KDC-MN-354 – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Diphenhydramine, sold as Benadryl, is the canonical first-generation antihistamine and the active ingredient in most over-the-counter sleep aids (ZzzQuil, Tylenol PM, Unisom Sleepminis). It blocks H1 receptors for allergy relief but also blocks muscarinic receptors, producing the classic anticholinergic side effect cluster (dry mouth, urinary retention, constipation, confusion). Long-term use, particularly in older adults, has been linked to cognitive impairment and possibly increased dementia risk in observational studies. Newer non-sedating antihistamines like cetirizine or loratadine are preferred for routine allergy control; diphenhydramine remains useful for acute allergic reactions and as an antiemetic. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Canonical 1946 sedating antihistamine, well-understood and thoroughly superseded on every therapeutic dimension

Look, diphenhydramine is almost the ideal negative example for what this library is supposed to surface. It was approved in 1946. It’s in Benadryl, ZzzQuil, Tylenol PM, and approximately every OTC sleep product on the drugstore shelf. The mechanism is textbook second-year pharmacology: potent H1 blockade (Ki ~16 nM) combined with broad muscarinic antagonism across M1-M5 (Ki ~70 nM). The sedation is a side effect that got marketed as a feature. Thats not a research hook, thats a liability someone repackaged.

The anticholinergic burden is the most scientifically active conversation around this compound right now, and the news is not good. The BEERS Criteria flag it explicitly as potentially inappropriate in older adults. Long-term use epidemiology associates it with meaningful dementia risk. The Anticholinergic Cognitive Burden scale uses it as a reference entry. So the “interesting” research angle here is essentially “how bad is this for brains” rather than any forward-looking therapeutic story.

On differentiation: second-generation antihistamines (cetirizine, fexofenadine, loratadine) were developed for the specific purpose of removing exactly what makes diphenhydramine problematic. They strip the CNS penetration, reduce the anticholinergic load, and retain the H1 efficacy. In allergy indications, the second-gen compounds are strictly better. Diphenhydramine survives as an OTC sleep aid because sleepiness is the desired endpoint there, not because it’s pharmacologically refined.

We’ll give it credit where it’s due: the evidence base is massive. Multiple approved indications, well-replicated pharmacokinetics (plasma half-life 4-8 hours, reasonable oral bioavailability), a clear human signal for its approved uses. But strong evidence for tired indications isn’t what this library tracks. What we care about is whether a serious investigator should spend time on it, and the answer is almost never unless they’re specifically studying anticholinergic burden mechanisms or running assay comparisons as a reference standard for H1 pharmacology.

The bench utility is real but narrow. It appears in receptor selectivity panels, ACB scoring research, and as a comparator in antihistamine profiling studies. Thats legitimate. It’s not the kind of indispensable probe that defines what’s possible in a research area. It’s more of a known quantity you include in a table to anchor your assay.

Honestly, the score of 30 probably feels generous given how thoroughly this compound has been superseded. The evidence quality axis pulls it up because 75 years of replicated pharmacology is hard to ignore. But novelty at 5 and mechanism at 12 are where the real story lives: this compound solved a problem in 1946 that was solved more elegantly by 1995. Research time is better spent elsewhere.

Novelty: 5
Mechanism promise: 12
In-category differentiation: 20
Evidence quality: 75
Translational signal: 55
Research bench value: 35

Rationale Diphenhydramine scores near-zero on novelty (1946 approval, OTC ubiquity) and mechanism promise (dual H1/muscarinic antagonism, both trivially understood); evidence quality is high but reflects 75 years of boring clinical confirmation, not frontier signal. No structural cap formally applies, but the raw calculation lands at 30 anyway.

First-generation H1 antihistamine + anticholinergic

An ethanolamine first-generation H1 antihistamine; the canonical sedating antihistamine and OTC sleep aid.

Abstract

Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine; CAS 58-73-1; molecular formula C17H21NO; molecular weight 255.36) is an ethanolamine first-generation H1 antihistamine developed at Parke-Davis and approved in 1946. The compound is the canonical sedating H1 blocker (Ki approximately 16 nM) with significant anticholinergic activity (M1-M5 antagonism, Ki approximately 70 nM). The combined activity produces sedation, dry mouth, blurred vision, and confusion (especially in elderly). Plasma half-life is approximately 4 to 8 hours. Approved indications: allergic conditions, motion sickness, parkinsonism, anaphylaxis. OTC sleep aid use in branded products (Tylenol PM, ZzzQuil) is widespread despite limited efficacy and concerning anticholinergic burden in elderly (associated with dementia risk in long-term use per BEERS criteria). The compound has dose-dependent abuse potential at high doses (deliriant effect from anticholinergic activity). Used as the canonical first-generation H1 antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-354Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-354

Diphenhydramine

Abstract

Read the full monograph